JP2021513996A5 - - Google Patents

Info

Publication number
JP2021513996A5
JP2021513996A5 JP2020544264A JP2020544264A JP2021513996A5 JP 2021513996 A5 JP2021513996 A5 JP 2021513996A5 JP 2020544264 A JP2020544264 A JP 2020544264A JP 2020544264 A JP2020544264 A JP 2020544264A JP 2021513996 A5 JP2021513996 A5 JP 2021513996A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
group
haloalkyl
independently selected
Prior art date
Application number
JP2020544264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513996A (ja
JP7387616B2 (ja
JPWO2019165043A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018919 external-priority patent/WO2019165043A2/en
Publication of JP2021513996A publication Critical patent/JP2021513996A/ja
Publication of JP2021513996A5 publication Critical patent/JP2021513996A5/ja
Publication of JPWO2019165043A5 publication Critical patent/JPWO2019165043A5/ja
Application granted granted Critical
Publication of JP7387616B2 publication Critical patent/JP7387616B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544264A 2018-02-22 2019-02-21 Pd-l1アンタゴニストとしてのインダン-アミン Active JP7387616B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633973P 2018-02-22 2018-02-22
US62/633,973 2018-02-22
PCT/US2019/018919 WO2019165043A2 (en) 2018-02-22 2019-02-21 Indane-amines as pd-l1 antagonists

Publications (4)

Publication Number Publication Date
JP2021513996A JP2021513996A (ja) 2021-06-03
JP2021513996A5 true JP2021513996A5 (https=) 2022-03-01
JPWO2019165043A5 JPWO2019165043A5 (https=) 2022-03-01
JP7387616B2 JP7387616B2 (ja) 2023-11-28

Family

ID=67687901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544264A Active JP7387616B2 (ja) 2018-02-22 2019-02-21 Pd-l1アンタゴニストとしてのインダン-アミン

Country Status (5)

Country Link
US (3) US10568874B2 (https=)
EP (1) EP3755311B1 (https=)
JP (1) JP7387616B2 (https=)
MA (1) MA51232A (https=)
WO (1) WO2019165043A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
JP7387616B2 (ja) * 2018-02-22 2023-11-28 ケモセントリックス,インコーポレイティド Pd-l1アンタゴニストとしてのインダン-アミン
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
AU2020276277B2 (en) 2019-05-15 2025-03-20 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
CN114555080B (zh) 2019-10-16 2025-10-10 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯胺
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
WO2021262627A1 (en) * 2020-06-23 2021-12-30 Chemocentryx, Inc. Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
US7786165B2 (en) * 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP2402320A1 (en) 2006-03-31 2012-01-04 Novartis AG Anorectic agents
DE102006017175A1 (de) 2006-04-12 2007-10-18 Robert Bosch Gmbh Balancierter Serienmischer für Hochfrequenzsignale
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
JP6417419B2 (ja) 2013-09-04 2018-11-07 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 免疫調節剤として有用な化合物
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
SI3041828T1 (sl) 2013-09-06 2018-10-30 Aurigene Discovery Technologies Limited 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3331860B1 (en) * 2015-08-07 2019-07-17 Boehringer Ingelheim International GmbH Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
NL1041468B1 (en) 2015-09-08 2017-03-22 Bosch Gmbh Robert Metal ring component of a drive belt for a continuously variable transmisson.
US20180354962A1 (en) * 2015-09-09 2018-12-13 Boehringer Ingelheim International Gmbh [{[2,3-Dihydro-1H-inden-1-yl]amino}-2H,3H-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
JP7075928B2 (ja) 2016-05-23 2022-05-26 中国医学科学院薬物研究所 フェニレート誘導体、調製及び医薬組成物及び使用
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
US11078192B2 (en) 2016-07-05 2021-08-03 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109689640B (zh) 2016-07-08 2022-01-04 百时美施贵宝公司 可用作免疫调节剂的化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
US10771492B2 (en) 2016-09-22 2020-09-08 Microsoft Technology Licensing, Llc Enterprise graph method of threat detection
JP7106572B2 (ja) 2016-12-20 2022-07-26 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な化合物
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3564237A4 (en) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
KR20190133714A (ko) 2017-03-27 2019-12-03 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 치환된 이소퀴놀린 유도체
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
WO2019034172A1 (zh) 2017-08-18 2019-02-21 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
CN118267479A (zh) 2017-09-25 2024-07-02 凯莫森特里克斯股份有限公司 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗
US11492375B2 (en) 2017-10-03 2022-11-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
WO2019120297A1 (zh) 2017-12-22 2019-06-27 上海海雁医药科技有限公司 免疫调节剂及其制法与医药上的用途
KR102666727B1 (ko) 2017-12-29 2024-05-21 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도
JP7214752B2 (ja) 2018-01-23 2023-01-30 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な2,8-ジアシル-2,8-ジアザスピロ[5.5]ウンデカン化合物
CA3088927C (en) 2018-02-05 2023-03-21 Abbisko Therapeutics Co., Ltd. Biaryl derivative, preparation method therefor and pharmaceutical use thereof
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
JP7387616B2 (ja) * 2018-02-22 2023-11-28 ケモセントリックス,インコーポレイティド Pd-l1アンタゴニストとしてのインダン-アミン
EP3759093B1 (en) 2018-03-01 2022-11-30 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2019174533A1 (zh) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2019192506A1 (en) 2018-04-03 2019-10-10 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
WO2020011209A1 (zh) 2018-07-11 2020-01-16 上海和誉生物医药科技有限公司 免疫抑制剂及其制备方法和在药学上的应用
WO2020011243A1 (en) 2018-07-12 2020-01-16 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20210300909A1 (en) 2018-07-19 2021-09-30 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
US20210269440A1 (en) 2018-07-19 2021-09-02 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
US20210347785A1 (en) 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
US20210236476A1 (en) 2018-08-29 2021-08-05 Chemocentryx, Inc. Methods of treating cancer with small molecule pd-l1 inhibitors
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
AU2020276277B2 (en) 2019-05-15 2025-03-20 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
SG11202112875UA (en) 2019-06-20 2021-12-30 Chemocentryx Inc Compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
CN114555080B (zh) 2019-10-16 2025-10-10 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯胺
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
WO2021262627A1 (en) 2020-06-23 2021-12-30 Chemocentryx, Inc. Methods of treating cancer using heteroaryl-biphenyl amide derivatives

Similar Documents

Publication Publication Date Title
JP2021513996A5 (https=)
US20230226092A1 (en) Cancer treatments based on gemcitabine prodrugs
JP2019527202A5 (https=)
JP2020528905A5 (https=)
US20230218655A1 (en) Cancer treatments
JP6005855B2 (ja) 血管破壊薬および低酸素を標的とする薬剤を含む併用療法
JP6021805B2 (ja) 腫瘍治療剤
JP2021502993A5 (https=)
CN113825756A (zh) 取代的多环羧酸、其类似物和其使用方法
WO2006069525A1 (en) Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
KR20240067907A (ko) Kras 돌연변이가 있는 암 환자의 치료
JP2021006576A (ja) Mdm2阻害剤とdnaメチルトランスフェラーゼ阻害剤との併用治療法
JP2006070032A (ja) 抗血管形成薬剤組成物
JPWO2019165043A5 (https=)
JP5840700B2 (ja) 共役3−(インドリル)−および3−(アザインドリル)−4−アリールマレイミド化合物および腫瘍処置におけるそれらの使用
JP2013514295A (ja) 3−(インドリル)−または3−(アザインドリル)−4−アリールマレイミド化合物および腫瘍処置におけるそれらの使用
CN101291675B (zh) 抗癌组合药物
JP6226981B2 (ja) 肝細胞癌を処置するためのvegfr−3阻害剤の使用
CN115403583B (zh) 一种靶向降解fak蛋白的化合物及其用途
WO2014048377A1 (zh) 治疗肿瘤的组合药物及其应用
JP2013504520A5 (https=)
WO2026026870A1 (zh) 环状内酯化合物及其医药用途
EA049653B1 (ru) Комбинированная терапия с применением ингибиторов prmt5 для лечения рака
EA050479B1 (ru) Комбинированная терапия с применением ингибиторов prmt5 для лечения рака
CN108135894A (zh) 肿瘤治疗剂